Madrigal Pharmaceuticals (MDGL) Financial Analysis & Valuation | Quarter Chart
Madrigal Pharmaceuticals (MDGL)
MDGLPrice: $527.28
Fair Value: 🔒
🔒score
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid horm... more
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the developme... more
Description
Shares
| Market Cap | $12.16B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | William J. Sibold |
| IPO Date | 2007-02-06 | CAGR | — |
| Employees | 528 | Website | www.madrigalpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MDGL chart loading...
Fundamentals
Technicals
| Enterprise Value | $15.47B | P/E Ratio | -41.19 |
| Forward P/E | 42.59 | PEG Ratio | — |
| P/S Ratio | 11.12 | P/B Ratio | 29.18 |
| P/CF Ratio | -59.16 | P/FCF Ratio | -46.23 |
| EPS | $-12.8 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 256.82% | Gross Margin | 0.93% |
| Operating Margin | -0.28% | Profit Margin | -0.27% |
| ROE | -0.5% | ROA | -0.25% |
| ROCE | -0.35% | Current Ratio | 3.5 |
| Quick Ratio | 3.16 | Cash Ratio | 0.69 |
| Debt/Equity | 0.64 | Interest Coverage | -11.68 |
| Altman Z Score | 9.08 | Piotroski Score | 2 |